Cross-Sector entity
Alkermes is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. Coverage clusters in market-trends, which accounts for 1 of those 2, with the remainder spread across 1 other category. LivaNova appears in 2 tracked Cross-Sector stories from February 26, 2026.
2 verified stories tracked
Last mentioned: Feb 26, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Alkermes is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. Coverage clusters in market-trends, which accounts for 1 of those 2, with the remainder spread across 1 other category. LivaNova appears in 2 tracked Cross-Sector stories from February 26, 2026. The tracked stories average 20 original sources each.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering LivaNova. Shared-story counts are live from our verified record — not editorial picks.
Mid-cap biotech and specialty pharma companies are demonstrating strong commercial maturation, led by record-breaking rare disease revenues and strategic consolidation. Key players like Mirum and Acadia are scaling rapidly, while Alkermes’ acquisition of Avadel signals a shift toward aggressive portfolio expansion in the neuroscience space.
The Q4 2025 earnings cycle for healthcare and health IT firms reveals a sector-wide shift toward AI-driven diagnostics and high-margin orphan drug commercialization. While medical device firms face cyclical equipment sales challenges, specialized biotech and diagnostic players like Veracyte and Soleno are reporting record profitability and rapid market penetration.
